STERIS

STERIS Plc engages in the provision of healthcare and life science product and service solutions. It operates through the following segments: Healthcare, Life Sciences, Applied Sterilization Technologies, and Dental. The Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. The Life Sciences segment designs, manufactures, and sells consumable products, equipment maintenance, specialty services, and capital equipment. The Applied Sterilization Technologies segment is involved in contract sterilization and testing services for medical device and pharmaceutical manufacturers. The Dental segment provides a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems. The company was founded in 1985 and is headquartered in Mentor, OH.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

STERIS plc reports 16% revenue growth and anticipates 7-8% growth in fiscal 2024

STERIS plc's Q4 2023 earnings call highlighted strong revenue growth, successful integration of Cantel Medical, and cost synergies exceeding projections. While challenges exist in the AST segment and concerns were raised about labor costs and free cash flow pressure, the outlook for fiscal 2024 indicates potential opportunities for growth.

STERIS plc reports mixed Q2 performance, optimistic about future opportunities

STERIS plc's Q2 2023 earnings call highlighted mixed performance across segments, with strong growth in Healthcare but challenges in the AST and Dental segments. The company remains optimistic about future opportunities, particularly with the Becton, Dickinson deal and updated financial outlook.

STERIS reports Q3 growth, faces margin pressures and supply challenges

STERIS delivered solid revenue growth despite challenges from divestitures and margin pressures.
The company's strategic acquisitions and focus on direct market access position it for future growth.
While facing some headwinds, STERIS remains confident in its long-term growth prospects.
Investors should monitor how the company navigates supply chain strains and capitalizes on bioprocessing demand.

STERIS reports strong Q4 earnings, eyes growth amid challenges

STERIS delivered robust Q4 2023 results with strong revenue growth and net income.
While facing challenges in certain segments, the company remains optimistic about growth opportunities.
Confidence in compliance with EPA regulations and a positive outlook for fiscal 2024.
Strategic capital allocation decisions and cost synergies driving financial performance.

STERIS reports solid Q1 earnings, eyes growth through acquisitions

STERIS' Q1 2024 performance was solid, driven by revenue growth in the healthcare segment. Challenges were seen in the AST and Dental segments due to inventory destocking. The upcoming acquisition and positive growth expectations in Life Sciences present opportunities for future growth.

STERIS reports strong Q2 performance amidst segment challenges

STERIS showcased robust financial performance in Q2 2024, driven by strong organic revenue growth and solid net income. While facing challenges in certain segments, the company remains optimistic about future growth opportunities and is actively managing its debt and cash flow.

STERIS reports strong Q3 earnings, updates 2024 outlook positively

STERIS showcased solid performance in Q3 2024, driven by strong healthcare and life sciences segments. Challenges in AST and Dental segments were noted, with opportunities seen in updated fiscal 2024 outlook and strategic discussions on margin dynamics and expansion.

STERIS reports 7% revenue growth, anticipates margin improvement ahead

STERIS demonstrated solid revenue growth and maintained free cash flow in line with guidance.
While facing margin challenges in certain segments, the company anticipates improvements ahead.
The outlook for organic revenue growth, adjusted EPS, and free cash flow remains positive for the full year.
Overall, STERIS is strategically positioned to capitalize on growth opportunities and address current challenges.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

STERIS Plc engages in the provision of healthcare and life science products and service solutions. It operates through the following segments: Healthcare, Life Sciences, Applied Sterilization Technologies, and Dental. The Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. The Life Sciences segment designs, manufactures, and sells consumable products, equipment maintenance, specialty services, and capital equipment. The Applied Sterilization Technologies segment is involved in contract sterilization and testing services for medical device and pharmaceutical manufacturers. The Dental segment offers a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems. The company was founded in 1985 and is headquartered in Dublin, Ireland.

Evoqua Water Technologies

PITTSBURGH--(BUSINESS WIRE)--Evoqua Water Technologies Closes Acquisition of Renal Business from STERIS

Evoqua Water Technologies Closes Acquisition of Renal Business from STERIS

Steris (STE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Steris (STE) Upgraded to Buy: Here's Why

The latest spin-off of STERIS' (STE) Renal Care business is expected to partly reduce the company's debt burden.

STERIS (STE) Plans Sale of Non-Core Arm for Debt Repayment

Evoqua Water Technologies Corp (NYSE: AQUA) has agreed to acquire the assets of the renal business of Steris PLC (NYSE: STE) for $196.3 million. The acquired renal business, historically operated by Steris' subsidiaries Mar Cor Purification and Cantel Medical, will strengthen Evoqua's medical water purification systems and aftermarket services offerings.

Evoqua Water To Acquire Steris' Renal Business For $196.3M

PITTSBURGH--(BUSINESS WIRE)--Evoqua Water Technologies Signs Definitive Agreement to Acquire Renal Business from STERIS

Evoqua Water Technologies Signs Definitive Agreement to Acquire Renal Business from STERIS

Accuray

Thermo Fisher Scientific

The Zacks Medical - Instruments industry is growing on COVID-support business gains. TMO, STE and ARAY are set to gain the most.

3 Top Medical Instruments Stocks to Counter Industry Headwinds

Steris (STE) reported earnings 30 days ago. What's next for the stock?

Steris (STE) Down 3.2% Since Last Earnings Report: Can It Rebound?

Solid growth across all three reporting segments drove STERIS' (STE) second-quarter fiscal 2022 revenues.

STERIS (STE) Q2 Earnings Surpass Estimates, Margins Down

STERIS plc (STE) CEO Dan Carestio on Q2 2022 results - Earnings Call Transcript

Steris (STE) delivered earnings and revenue surprises of 8.74% and 3.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Steris (STE) Beats Q2 Earnings and Revenue Estimates

DUBLIN, IRELAND , Nov. 02, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2022 second quarter ended September 30, 2021. Revenue as reported for the quarter increased 58% to $1,197 million compared with $756 million in the second quarter of fiscal 2021. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 12% for the second quarter of fiscal 2022 as compared to the second quarter of fiscal 2021.

STERIS Announces Financial Results for Fiscal 2022 Second Quarter

Henry Schein

IDEXX Laboratories

Omnicell

With the pandemic raging on, testing, vaccine and therapeutic makers are witnessing huge market adoption of their COVID-related support products in Q3.

Medical Products Stock Earnings on Nov 2: IDXX, STE & More

Strong gains from the recent Cantel Medical buyout as well as the addition of a new Dental arm are expected to have contributed STERIS' (STE) Q2 performance.

STERIS (STE) to Report Q2 Earnings: What's in the Cards?

Dublin, Ireland, Oct. 20, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2022 second quarter financial results at 10:00 a.m. ET on November 3, 2021. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.

STERIS to Host a Conference Call for Fiscal 2022 Second Quarter Financial Results on November 3, 2021

Pool

Roper Technologies

Teleflex

Visa

Villere & Co. was established in 1911 and has been operated by the Villere family for over a decade. The team invests selectively and independently—taking a long-term perspective.

The Top 5 Holdings of Villere & Co.

Investors are optimistic about STERIS (STE) owing to elevated consumer demand and rebound in procedure volumes and raised 2022 outlook.

Here's Why You Should Add STERIS (STE) to Your Portfolio

Steris (STE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Steris (STE) Upgraded to Buy: What Does It Mean for the Stock?

Steris (STE) Down 1.5% Since Last Earnings Report: Can It Rebound?

STERIS (STE) ended first-quarter fiscal 2022 with better-than-expected results and strong segmental performance, driving the top line.

Here's Why You Should Add STERIS (STE) to Your Portfolio Now

Associated Banc-Corp

Brookfield Asset Management

Brookfield Infrastructure Partners L.P.

Bank of Hawaii

Cable One

Cboe Global Markets

Cullen/Frost Bankers

Dover

FNCB Bancorp

Goldman Sachs

Mercantile Bank

McKesson

MGE Energy

Martin Marietta Materials

MVB Financial

NBT Bancorp

North American Energy Partners

Peoples Bancorp of North Carolina

Principal Financial Group

Peoples Financial Services

All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 10.3% and a median increase of 6.7%.

21 Upcoming Dividend Increases Including 1 Dividend King

Badger Meter

Broadridge Financial

International Bancshares Corp.

IF Bancorp

Leggett & Platt

Nordson

United Community Banks

Westlake Chemical

This article series covers dividend changes every week.

Dividend Increases: August 7-13, 2021

STERIS (STE) reported better-than-expected revenues for first-quarter fiscal 2022 on strong segmental performance driving the top line.

STERIS (STE) Q1 Earnings Beat Estimates, 2022 Guidance Up

STERIS plc (STE) CEO Dan Carestio on Q1 2022 Results - Earnings Call Transcript

Steris (STE) delivered earnings and revenue surprises of 17.33% and 7.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Steris (STE) Q1 Earnings and Revenues Top Estimates

DUBLIN, IRELAND, Aug. 09, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2022 first quarter ended June 30, 2021. Revenue as reported for the quarter increased 45% to $968.4 million compared with $668.9 million in the first quarter of fiscal 2021. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 21% for the first quarter of fiscal 2022 as compared to the first quarter of fiscal 2021, which was negatively impacted by the pandemic.

News for STERIS Stock (STE)